Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541303 · ClinicalTrials.gov registry record · Early Phase 1
Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery
A Early Phase 1 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 124
- Enrollment target
NCT04541303 is a Early Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 124 participants.
The verdict
NCT04541303, a Early Phase 1 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
Bleeding after Mohs micrographic surgery for skin cancer is a low risk complication that can occur. This study aims to determine the effect of a drug, often used to reduce bleeding, called tranexamic acid when applied topically to the skin wound after surgery.
Interventions
- DRUG Tranexamic acid
- DRUG normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2021-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04541303
The ClinicalTrials.gov registry entry for NCT04541303 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tranexamic acid is the first listed.
NCT04541303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04541303 about?
NCT04541303 is a clinical study titled "Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery". Bleeding after Mohs micrographic surgery for skin cancer is a low risk complication that can occur. This study aims to determine the effect of a drug, often used to reduce bleeding, called tranexamic acid when applied topically to the skin wound after surgery.
What is the current status of trial NCT04541303?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 124 participants. The study started on 2020-10-08. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04541303?
The interventions under investigation include: Tranexamic acid (DRUG), normal saline (DRUG).
Who is sponsoring clinical trial NCT04541303?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.